Patents Assigned to ASCENEURON SA
-
Patent number: 12016852Abstract: Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims, can be employed, inter alia, for the treatment of taupathies and Alzheimer's disease.Type: GrantFiled: August 22, 2019Date of Patent: June 25, 2024Assignee: Asceneuron SAInventors: Anna Quattropani, Grant Wishart, Santosh S. Kulkarni, Paul Rakesh
-
Patent number: 11795165Abstract: Compounds of formula (I?), wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R??, m and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 22, 2019Date of Patent: October 24, 2023Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Grant Wishart, Paul Rakesh
-
Patent number: 11731972Abstract: Compounds of formula (I), wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 22, 2019Date of Patent: August 22, 2023Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Paul Rakesh, Awadut Gajendra Giri
-
Patent number: 11612599Abstract: Compounds of formula (I), wherein A, R, W, Q, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: February 24, 2017Date of Patent: March 28, 2023Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 11591327Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.Type: GrantFiled: May 18, 2020Date of Patent: February 28, 2023Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Dawn V. Toronto, David Malcolm Crowe
-
Patent number: 11458140Abstract: Compounds of formula (I), wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 24, 2017Date of Patent: October 4, 2022Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 11261183Abstract: Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 24, 2017Date of Patent: March 1, 2022Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 11213525Abstract: Compounds of formula (I), wherein A, R, W, Q, L, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 24, 2017Date of Patent: January 4, 2022Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 11046712Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.Type: GrantFiled: May 15, 2019Date of Patent: June 29, 2021Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 10995090Abstract: Compounds of formula (I), wherein R?, R?, R, X, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: August 24, 2017Date of Patent: May 4, 2021Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Publication number: 20200385375Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.Type: ApplicationFiled: May 18, 2020Publication date: December 10, 2020Applicant: Asceneuron SAInventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Dawn V. TORONTO, David Malcolm CROWE
-
Patent number: 10696668Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.Type: GrantFiled: February 24, 2017Date of Patent: June 30, 2020Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Dawn V. Toronto, David Malcolm Crowe
-
Patent number: 10556902Abstract: Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.Type: GrantFiled: February 24, 2017Date of Patent: February 11, 2020Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 10336775Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.Type: GrantFiled: August 27, 2015Date of Patent: July 2, 2019Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
-
Patent number: 9505769Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.Type: GrantFiled: June 12, 2014Date of Patent: November 29, 2016Assignee: Asceneuron SAInventors: Anna Quattropani, Santosh S. Kulkarni, Kathiravan Murugesan, Joydeep Banerjee
-
Publication number: 20160137648Abstract: The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.Type: ApplicationFiled: June 12, 2014Publication date: May 19, 2016Applicant: ASCENEURON SAInventors: ANNA QUATTROPANI, SANTOSH S. KULKARNI, KATHIRAVAN MURUGESAN, JOYDEEP BANERJEE